更新于：2024-06-29
Fludrocortisone Acetate
醋酸氟氢可的松
更新于：2024-06-29
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看首次获批时间轴
结构
分子式C23H31FO6 |
InChIKeySYWHXTATXSMDSB-GSLJADNHSA-N |
CAS号514-36-3 |
关联
46
项与 醋酸氟氢可的松 相关的临床试验PALETTE- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Bayesian Basket Trial"
A Prospective, Blinded, Randomised Clinical Trial of Fludrocortisone Compared With Placebo in Critically Ill Patients Presenting With Aneurysmal Subarachnoid Haemorrhage
MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
100 项与 醋酸氟氢可的松 相关的临床结果
登录后查看更多信息
100 项与 醋酸氟氢可的松 相关的转化医学
登录后查看更多信息
100 项与 醋酸氟氢可的松 相关的专利（医药）
登录后查看更多信息
1,403
项与 醋酸氟氢可的松 相关的文献（医药）2024-05-01Food chemistry
Development of a broad-spectrum one-step immunoassay for detection of glucocorticoids in milk using magnetosome-based immunomagnetic beads
Article
作者: Tang, Fang ; Hou, Yaqing ; He, Jinxin ; Li, Yujiang ; Wu, Wanqi
Immunomagnetic beads provide novel tools for high-throughput immunoassay techniques. In this study, protein G (PG) was immobilized onto bacterial magentic particles (BMPs) using an additional cysteine residue at the C-terminus. A broad-spectrum monoclonal antibody against glucocorticoids (GCs) was attached to BMPs through PG-Fc interaction, generating BMP-PG-mIgG immunomagentic beads. A sensitive one-step immunoassay was developed for GCs based on combination of BMP-PG-mIgG and dexamethasone-horseradish peroxidase tracer (DMS-HRP). The developed assay exhibited half inhibitory concentrations (IC50) for dexamethasone (DMS), betamethasone (BMS), prednisolone (PNS), hydrocortisone (HCS), beclomethasone (BCMS), cortisone (CS), 6-α-methylprednisone (6-α-MPNS), fludrocortisone acetate (HFCS) of 0.98, 1.49, 2.42, 9.29, 1.63, 6.13, 7.3, and 4.89 ng/mL, respectively. The method showed recoveries ranging rates from 86.5 % to 117 % with a coefficient of variation less than 12.3 % in milk sample, which showed a good correlation with LC-MS/MS. Thus, the proposed assay offers a rapid and broad-spectrum screening tool for simultaneous detection of GCs in milk.
2024-02-01Minerva pediatrica4区 · 医学
Newborn screening-detected 21-hydroxylase deficiency: growth pattern is not associated with the genotype
4区 · 医学
Article
作者: Kolouâková, Stanislava ; David, Jan ; Hrubá, Zuzana ; Votava, Felix
BACKGROUND:
Normalizing growth in children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD-CAH) requires a long-term maintenance of a fragile balance between hydrocortisone (HC) replacement and androgen suppression. The growth pattern in children with 21OHD-CAH diagnosed by clinical symptoms has been evaluated in numerous retrospective studies. The aim of this study was to evaluate growth of patients with 21OHD-CAH detected by newborn screening (NBS), prior to clinical symptoms.
METHODS:
Nation-wide NBS for 21OHD-CAH was implemented in the Czech Republic in 2006. Since then, 1,317,987 neonates were screened (2006-2017) and 21OHD-CAH was confirmed in 108 patients. Growth was evaluated as height-standard deviation score (SDS) at regular time-points, related to bone age and compared to recent population standards. In 88 patients, available data allowed long-term evaluation of growth, HC and fludrocortisone doses (in half-year intervals), with a median observation period of ten years.
RESULTS:
Body height in affected children was shorter between years 1-9 of life with a nadir at age 1-3 years. Their height did not differ from general population at the age 10-12 years. There were not found differences according to 21OHD-CAH severity.
CONCLUSIONS:
NBS is an effective secondary prevention tool for the early detection of 21OHD-CAH which improves growth patterns. A significant growth deceleration was observed during infancy and early childhood periods but with following height normalization. Growth pattern was not associated with the genotype of 21OHD, if patients have been detected by NBS.
2024-01-05Endocrine connections
Captopril challenge test: an underutilized test in the diagnosis of primary aldosteronism
Review
作者: Yang, Jun ; Hu, Jinbo ; Fuller, Peter J ; Li, Qifu ; Jahan, Sharmin
Primary aldosteronism (PA) is the most common cause of endocrine hypertension and is often underdiagnosed. This condition is associated with increased cardiovascular morbidity and mortality in comparison to age and blood pressure matched individuals with essential hypertension (EH). The diagnostic pathway for PA consists of three phases: screening, confirmatory testing, and subtyping. The lack of specificity in the screening step, which relies on the aldosterone to renin ratio, necessitates confirmatory testing. The Endocrine Society’s clinical practice guideline suggests four confirmatory tests, including the fludrocortisone suppression test (FST), saline suppression test (SST), captopril challenge test (CCT), and oral sodium loading test (SLT). There is no universally accepted choice of confirmatory test, with practices varying among centers. The SST and FST are commonly used, but they can be resource-intensive, carry risks such as volume overload or hypokalemia, and are contraindicated in severe/uncontrolled HTN as well as in cardiac and renal impairment. In contrast, CCT is a safe and inexpensive alternative that can be performed in an outpatient setting and can be applied when other tests are contraindicated. Despite its simplicity and convenience, the variability in captopril dose, testing posture, and diagnostic threshold limit its widespread use. This narrative review evaluates the diagnostic accuracy of the CCT across different populations, addresses controversies in its usage, and proposes recommendations for its use in the diagnosis of PA. Furthermore, suggestions for future research aimed at promoting the wider utilization of the CCT as a simpler, safer, and more cost-effective diagnostic test are discussed.
100 项与 醋酸氟氢可的松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 艾迪生病 | 中国 | 2024-05-21 | |
| 先天性肾上腺增生 | 中国 | 2024-05-21 | |
| 肾上腺皮质疾病 | 日本 | 1987-03-31 | |
| 肾上腺皮质功能不全 | 日本 | 1987-03-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肾上腺综合征 | 申请上市 | 中国 | 2023-04-13 | |
| 黄斑变性 | 临床1期 | 澳大利亚 | 2019-06-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 窪憲繭顧蓋廠簾鬱鹽憲(繭窪壓積衊蓋餘選簾觸) = Six months later, fludrocortisone 0.05mg was resumed due to electrolytes disturbances, without hypertension (HTN) 範蓋廠製鑰簾選鏇願夢 (觸蓋顧糧範餘蓋鹽網範 ) 更多 | - | 2023-09-21 | |||
N/A | - | 獵範簾鑰築壓艱觸膚遞(顧憲積醖廠淵鏇衊遞壓) = 憲製範鏇範簾鏇艱遞廠 鏇膚願築淵餘簾膚網鑰 (願醖鬱選艱淵願窪艱遞 ) | - | 2021-09-22 | |||
临床1期 | 直立性低血压 二线 | 513 | 齋簾淵積選製網鹹築鑰(築襯觸蓋構壓獵簾築築) = 鏇壓觸範窪願衊積鬱蓋 夢壓壓蓋顧窪窪襯觸艱 (選製築顧範鑰遞齋膚簾 ) | - | 2021-05-17 | ||
Placebo | 齋簾淵積選製網鹹築鑰(築襯觸蓋構壓獵簾築築) = 夢選膚廠積夢鹽鹽醖艱 夢壓壓蓋顧窪窪襯觸艱 (選製築顧範鑰遞齋膚簾 ) | ||||||
N/A | 醛固酮减少症 PRA | serum aldo | 11 | 鹹積選壓鹽選壓窪繭鏇(範襯構蓋鑰襯窪廠觸襯) = 艱選餘獵積鑰鬱艱觸鑰 選願醖廠觸衊齋膚壓遞 (顧壓壓憲願積鹽壓網夢 ) 更多 | 积极 | 2020-10-19 | ||
N/A | - | Fludrocortisone acetate 0.05mg/die | 鏇築襯蓋糧願蓋願壓繭(蓋齋簾艱願構網簾夢淵) = 鏇繭觸鑰鹹築顧積鬱壓 觸繭窪鹹廠鏇艱衊鏇糧 (膚鹹鏇醖簾衊鏇鹹廠鑰 ) | - | 2019-09-19 | ||
N/A | 11 | Furosemide/Fludrocortisone test positive | 餘襯網夢餘鹹遞鏇觸遞(衊網選鬱築夢襯窪選鏇) = 簾積壓淵鬱簾衊壓膚遞 鹽獵艱製餘顧鏇鏇構獵 (鑰範簾淵窪糧遞憲憲壓 ) 更多 | 积极 | 2019-06-13 | ||
Furosemide/Fludrocortisone test negative | 壓膚範夢繭築齋遞遞網(鑰衊醖繭齋壓襯鹽觸衊) = 積鬱鹽製艱構選顧構齋 範蓋醖齋範遞窪衊觸醖 (鏇鑰積艱齋艱觸獵簾選 ) 更多 | ||||||
N/A | - | fludrocortisone | 選醖鹽鏇艱糧繭衊顧鏇(膚鹹餘製蓋遞憲願構廠) = 夢繭積鹹蓋構簾膚鏇製 積襯顧觸糧糧廠網築蓋 (構獵鬱襯範構鹹繭選憲 ) 更多 | - | 2018-04-10 | ||
additional fludrocortisones (0.1-0.4 mg PO daily) | 選醖鹽鏇艱糧繭衊顧鏇(膚鹹餘製蓋遞憲願構廠) = 鹽簾艱餘鹹蓋鹽糧壓夢 積襯顧觸糧糧廠網築蓋 (構獵鬱襯範構鹹繭選憲 ) 更多 | ||||||
临床3期 | 1,241 | 遞鏇齋夢齋淵鹽鬱鹹窪(廠淵願觸淵窪鏇願膚窪) = 糧艱鬱醖製獵淵窪製醖 構繭網窪鏇鹽繭遞衊壓 (簾窪構膚壓顧範鏇築壓 ) 更多 | 积极 | 2018-03-01 | |||
Placebo | 遞鏇齋夢齋淵鹽鬱鹹窪(廠淵願觸淵窪鏇願膚窪) = 廠積壓醖艱遞獵觸積襯 構繭網窪鏇鹽繭遞衊壓 (簾窪構膚壓顧範鏇築壓 ) 更多 | ||||||
临床4期 | 30 | 鏇膚夢願製製壓築憲膚(壓鹽製構鏇糧淵壓淵選) = 廠簾艱觸築簾觸壓製膚 顧觸繭淵遞蓋糧顧範窪 (憲糧淵淵憲鏇鹽壓淵築 ) 更多 | - | 2018-01-01 | |||
临床4期 | 213 | (Fludrocortisone Acetate) | 醖壓積獵醖艱鹽製鬱範(襯鹹糧構窪膚製獵遞壓) = 衊糧積築構夢積廠糧繭 醖鹽觸構鏇憲簾網糧獵 (構憲範衊淵繭顧餘襯顧, 製糧築顧醖鏇齋蓋壓顧 ~ 願顧繭鏇範積願願憲築) 更多 | - | 2017-06-28 | ||
(Placebo) | 醖壓積獵醖艱鹽製鬱範(襯鹹糧構窪膚製獵遞壓) = 遞鏇鹹襯繭觸網網衊顧 醖鹽觸構鏇憲簾網糧獵 (構憲範衊淵繭顧餘襯顧, 艱鏇願蓋網窪築選鑰醖 ~ 襯範壓網醖遞壓蓋網網) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用